Document is current
Any future updates will be listed below
-
Authors
Cheang, Iokfai
Yao, Wenming
Zhou, Yanli
Zhu, Xu http://orcid.org/0000-0002-4347-3639
Ni, Gehui
Lu, Xinyi
Liao, Shengen
Gao, Rongrong
Zhou, Fang
Shen, Jiangang
Leung, Alice Yeuk Lan
Jiang, Meng
Kong, Hong
Bai, Ling
Mahemuti, Ailiman
Yuan, Haitao
Dong, Yu-Gang
Wong, Chun-Ka
Xu, Qinghua
Zhang, Gaoxing
Wu, Jianhua
Lu, Qi
Zhang, Junhai
Cha, Chunxi
Ren, Qian
Fu, Lu
Wang, Bing
Xu, Yongshun
Hu, Houxiang
Dong, Jing
Shang, Zhuo
Yu, Chaoping
Li, Songsen
Yao, Chen
Gao, Lingling
Zhang, Haifeng
Rosenzweig, Anthony http://orcid.org/0000-0001-6387-0386
Jia, Zhenhua http://orcid.org/0000-0001-5132-1099
Li, Xinli http://orcid.org/0000-0002-6794-1468
,
- License Information
-
More Information
Article History
Received: 28 November 2023
Accepted: 1 July 2024
First Online: 2 August 2024
Competing interests
: X. Li and Z.J. are associate fellows at the State Key Laboratory for Innovation and Transformation of Luobing Theory. X. Li and H.Z. are associate fellows at the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine. X. Li reports receiving grant support (all grant support listed paid to the First Affiliated Hospital with Nanjing Medical University) from Novartis and the China Heart Failure Center and receiving lecture fees and consulting fees from AstraZeneca, Bayer, Novartis, Roche and Yiling. Z.J. reports affiliation with Hebei Yiling Hospital, a nonprofit medical institution, which is a completely independent legal entity from Shijiazhuang Yiling Pharmaceutical. Z.J. is the spouse of R.W., who holds shares and serves as a director of Shijiazhuang Yiling Pharmaceutical. Z.J. has fully disclosed these interests to the research committee and has developed an approved plan to manage any potential conflicts that may arise from such an arrangement and ensured the scientificity, objectivity and authority of the research results. H.Z. reports receiving lecture fees from AstraZeneca, Bayer, Novartis and Servier. I.C. reports receiving lecture fees from Haoyishu and Novartis. W.Y. reports receiving lecture fees from Bayer, Novartis, Sanofi and Yiling. Y.Z. reports receiving lecture fees from Novartis. S. Liao reports receiving lecture fees from Novartis. J.W. reports receiving lecture fees from AstraZeneca and Novartis. C.C. reports receiving lecture fees and consulting fees from AstraZeneca, Bayer and Pfizer. Q.R. reports receiving lecture fees and consulting fees from Bayer, Qilu pharmaceutical and China Medical System. No other potential competing interests relevant to this article are reported.
